CytomX Therapeutics 과거 순이익 실적
과거 기준 점검 0/6
CytomX Therapeutics은 연평균 48.1%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 18.2%의 비율로 증가했습니다.
핵심 정보
48.14%
순이익 성장률
55.42%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | 18.24% |
| 자기자본이익률 | -18.48% |
| 순이익률 | -174.84% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
분석 기사 • May 13
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • May 11
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) defied analyst predictions to release its first-quarter results, which were...
내러티브 업데이트 • Apr 23
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects
Analysts have lifted their average price target on CytomX Therapeutics by several dollars into the low to mid teens, citing stronger confidence in late line colorectal cancer data and updated views on the probability of approval for varsetatug masetecan and CX-2051. Analyst Commentary Bullish analysts are reworking their models after the latest Phase 1 expansion data for varsetatug masetecan in late line colorectal cancer and CX-2051 in colon cancer, with several firms lifting price targets into the low to high teens.내러티브 업데이트 • Apr 09
CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path
Analysts have nudged the fair value estimate for CytomX Therapeutics to $13.67 from $13.44, citing a wave of higher price targets across the Street following positive Phase 1 expansion data in late line colorectal cancer and updated views on key pipeline assets. Analyst Commentary Street research has shifted meaningfully in recent days, with multiple firms raising price targets and at least one upgrade from a major bank, all keyed to the latest Phase 1 expansion data in late line colorectal cancer and updated views on CytomX Therapeutics' pipeline.내러티브 업데이트 • Mar 26
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis
Analysts have lifted their price targets on CytomX Therapeutics by several dollars per share, with the updated fair value estimate moving from $9.00 to about $13.44, citing stronger confidence in late-line colorectal cancer data and higher assumed profitability for key pipeline assets. Analyst Commentary Street research on CytomX Therapeutics has turned more constructive following updated clinical data in late-line colorectal cancer and corporate updates around key pipeline assets such as varsetatug masetecan, also referenced as Varseta-M, and CX-2051.Seeking Alpha • Mar 16
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
Summary CytomX Therapeutics, Inc. receives a speculative Buy upgrade following promising new mCRC data for lead asset Varseta-M (CX-2051). Varseta-M shows a clear dose response and manageable safety profile with prophylactic measures, supporting the potential for a pivotal trial in 2027. CTMX valuation is highly dependent on Varseta-M in 3L+ mCRC, with risk-adjusted NPV modeled at $894M and a fully diluted fair value estimated at $7.15 per share. Significant dilution risk exists due to funding needs, but mCRC data validates CytomX’s platform, offering optionality for pipeline expansion. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 11
CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis
Analyst price targets for CytomX Therapeutics have moved higher by a few dollars, with the latest $2 and $3.50 target increases reflecting reassessments of fair value, updated profit margin assumptions, and a very large future P/E multiple cited by recent Street research. Analyst Commentary Recent Street research on CytomX Therapeutics clusters around higher price targets, fresh coverage and updated profit margin assumptions, all tied to the potential implied by a very large future P/E multiple.
내러티브 업데이트 • Feb 25
CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing
Analysts have nudged their price targets on CytomX Therapeutics higher by a few dollars, reflecting updated assumptions around slightly firmer revenue trends, a modestly lower profit margin profile, and a higher future P/E multiple in recent research from firms such as Barclays, Guggenheim, and Piper Sandler. Analyst Commentary Bullish analysts are framing the recent price target moves as a reflection of refreshed views on CytomX Therapeutics’ ability to execute on its plan, support revenue trends, and justify a higher P/E multiple over time.내러티브 업데이트 • Feb 11
CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential
Analysts have lifted their price targets on CytomX Therapeutics by a few dollars, citing updated fair value assumptions to about $9.00, modest tweaks to projected revenue declines and profit margins, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on CytomX Therapeutics has centered on modestly higher price targets and updated assumptions for fair value, revenue trends, and profit margins, along with a higher assumed future P/E multiple.분석 기사 • Jan 28
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Despite an already strong run, CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have been powering on, with a gain of...내러티브 업데이트 • Jan 27
CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing
Narrative Update The analyst price target for CytomX Therapeutics has moved modestly higher to about US$10.00 per share, as analysts factor in slightly better profit margin expectations and a somewhat lower implied future P/E multiple following recent bullish initiation and target raises from several firms. Analyst Commentary Recent research updates point to a more constructive stance on CytomX Therapeutics, with bullish analysts assigning higher price targets and initiating coverage with a positive angle.내러티브 업데이트 • Jan 11
CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program
Analysts have updated their price target on CytomX Therapeutics to US$7, with the shift tied to renewed confidence in CX-2051 after recent colorectal cancer data highlighted how challenging objective responses are in this setting and how the program still stands out to many on the Street. Analyst Commentary Bullish analysts are leaning into the idea that CX-2051 could be differentiated in colorectal cancer, especially after recent Phase 2 data from another company underscored how difficult it is to achieve objective responses in this setting.내러티브 업데이트 • Dec 20
CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline
Analysts have raised their price target on CytomX Therapeutics, lifting estimated fair value from about $8.00 to roughly $9.80 per share. They cite growing confidence in the risk to benefit profile and blockbuster potential of CX 2051, supported by recent colorectal cancer data comparisons and stronger projected profit margins despite a higher discount rate.내러티브 업데이트 • Dec 06
CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential
Analysts have modestly raised their price target on CytomX Therapeutics to $7.00, citing growing confidence in the risk reward profile and the blockbuster potential of lead colorectal cancer candidate CX-2051. This follows supportive sector readthroughs and solid cash runway visibility.내러티브 업데이트 • Nov 22
CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer
Analysts have increased their price target for CytomX Therapeutics from $6.14 to $7.07 per share, citing growing confidence in the risk-to-benefit profile and blockbuster potential of the company's lead clinical program. This adjustment is based on recent industry data and supportive coverage.분석 기사 • Nov 13
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Today is shaping up negative for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders, with the analysts delivering a...내러티브 업데이트 • Nov 05
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.내러티브 업데이트 • Oct 22
Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target
Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.분석 기사 • Oct 18
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...분석 기사 • Aug 14
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders won't be pleased to see that the share price has had a very...내러티브 업데이트 • Aug 11
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.분석 기사 • Jun 18
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • May 20
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...분석 기사 • May 16
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) just released its quarterly report and things are looking bullish. Statutory...분석 기사 • Apr 05
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Unfortunately for some shareholders, the CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has dived 26% in the...
새로운 내러티브 • Feb 09
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.분석 기사 • Feb 04
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have had a horrible month, losing 26% after a relatively good period...분석 기사 • Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Those holding CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares would be relieved that the share price has rebounded 26...분석 기사 • Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
With a price-to-sales (or "P/S") ratio of 0.7x CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) may be sending very bullish...Seeking Alpha • Jul 15
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Summary CytomX Therapeutics develops innovative oncology treatments using its Probody platform, creating conditionally activated biologics that increase drug efficiency and reduce side effects. Strategic partnerships with leading companies like Amgen, Astellas, and Bristol Myers Squibb leverage CTMX's Probody platform for drug development. The pipeline includes early-stage drugs CX-904, CX-2051, and CX-801, with preclinical programs. CTMX has a short cash runway and potential dilution risks in the next few years. I ultimately rate CTMX a “hold” due to balanced positives and negatives, but I think it's worth adding to your watchlist. Read the full article on Seeking Alpha분석 기사 • Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
The CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has fared very poorly over the last month, falling by a...매출 및 비용 세부 내역
매출 및 비용 세부 내역
CytomX Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 36 | -62 | 30 | 67 |
| 31 Dec 25 | 76 | -20 | 29 | 67 |
| 30 Sep 25 | 114 | 28 | 28 | 62 |
| 30 Jun 25 | 141 | 48 | 30 | 68 |
| 31 Mar 25 | 148 | 42 | 31 | 80 |
| 31 Dec 24 | 138 | 32 | 30 | 83 |
| 30 Sep 24 | 127 | 14 | 32 | 88 |
| 30 Jun 24 | 120 | 11 | 31 | 83 |
| 31 Mar 24 | 119 | 17 | 30 | 79 |
| 31 Dec 23 | 101 | -1 | 30 | 78 |
| 30 Sep 23 | 95 | -10 | 30 | 73 |
| 30 Jun 23 | 79 | -42 | 34 | 87 |
| 31 Mar 23 | 68 | -71 | 38 | 97 |
| 31 Dec 22 | 53 | -99 | 40 | 107 |
| 30 Sep 22 | 21 | -149 | 42 | 129 |
| 30 Jun 22 | 27 | -143 | 43 | 127 |
| 31 Mar 22 | 30 | -132 | 40 | 122 |
| 31 Dec 21 | 37 | -116 | 39 | 114 |
| 30 Sep 21 | 66 | -72 | 39 | 100 |
| 30 Jun 21 | 66 | -64 | 36 | 95 |
| 31 Mar 21 | 67 | -61 | 36 | 92 |
| 31 Dec 20 | 68 | -65 | 36 | 113 |
| 30 Sep 20 | 92 | -54 | 36 | 127 |
| 30 Jun 20 | 85 | -63 | 36 | 131 |
| 31 Mar 20 | 78 | -76 | 37 | 138 |
| 31 Dec 19 | 27 | -133 | 37 | 132 |
| 30 Sep 19 | 61 | -99 | 37 | 123 |
| 30 Jun 19 | 62 | -99 | 36 | 123 |
| 31 Mar 19 | 75 | -83 | 36 | 118 |
| 31 Dec 18 | 60 | -85 | 34 | 104 |
| 30 Sep 18 | 75 | -52 | 32 | 96 |
| 30 Jun 18 | 87 | -39 | 30 | 98 |
| 31 Mar 18 | 74 | -50 | 27 | 100 |
| 31 Dec 17 | 72 | -43 | 26 | 92 |
| 30 Sep 17 | 51 | -58 | 23 | 87 |
| 30 Jun 17 | 30 | -62 | 22 | 71 |
| 31 Mar 17 | 24 | -51 | 21 | 56 |
| 31 Dec 16 | 15 | -59 | 20 | 55 |
| 30 Sep 16 | 11 | -57 | 19 | 49 |
| 30 Jun 16 | 9 | -57 | 18 | 45 |
| 31 Mar 16 | 8 | -50 | 16 | 37 |
| 31 Dec 15 | 8 | -42 | 13 | 28 |
| 30 Sep 15 | 8 | -36 | 11 | 23 |
| 30 Jun 15 | 8 | -26 | 8 | 18 |
양질의 수익: CTMX 은(는) 현재 수익성이 없습니다.
이익 마진 증가: CTMX는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CTMX는 수익성이 없지만 지난 5년 동안 연평균 48.1%의 속도로 손실을 줄였습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 CTMX의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: CTMX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CTMX는 현재 수익성이 없으므로 자본 수익률이 음수(-18.48%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 23:13 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
CytomX Therapeutics, Inc.는 19명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |